Health Work Programme 2011- FP7 (5th year calls) презентация

Типы программ 7РП Европейского союза Cooperation (сотрудничество) – Ideas (идеи) – Реople (люди) - Capacities (cпособности) – Joint Research Projects (совместные исслед. проекты) – Euroatom (евроатом)

Приоритеты научной и науч- но-технической деятельности Европейского союза 1.Energy (Энергетика ) 2.Environment (including Climate Change) (Окружающая среда, включая изменения климата) 3.Food, Agriculture and Fishery, Biotechnology (Питание, сельское и рыбное хозяйство,биотехнологии) 4.Нealth(Здоровье) 5. Information and Communication Technologies (Информационные и коммуникационные технологии) 6. Nanosciences, Nanotechnologies, Materials and new Production Technologies (Нанонауки, нанотехнологии, материалы и новые производственные технологии ) 7. Socio-economic sciences and Humanities (Социально-экономические и гуманитарные науки) 8. Transport (including Aeronautics) (Транспорт, включая аэронавтику) 9. Security (Безопасность) По приоритетам Еврокомиссия объявляет ежегодные конкурсы

Схемы финанси- рования Collaborative projects (совместные проекты); Networks of excellence (сети превосходства) Coordination and support actions (работы по координации и поддержке) Individual projects (индивидуальные проекты) Support for training and career development of researches (поддержка совершенствования и карьерного роста исследователей)

Совместные проекты Выполняются консорциумами из пред-ставителей различных стран, проекты преследуют задачи: получение новых знаний, создание новых технологий и продукции, выполняются в рамках приоритетов по различным темам, предложено 3 типа совместных проектов (малые, средние и крупные), проекты могут быть ориентированы на специа-льные группы, например, SME.

Сети превосходства Сети превосходства Поддерживают совместные программы ряда организаций (Joint Programme Activities), объединяющих свою деятельность в опре-деленной области исследований в ходе длительной кооперации Работы по координации и поддержке Поддерживают деятельность по координации и поддержке научных исследований (создание сетей, обмены учеными и информацией, транснациональный доступ к инфраструктурам и исследованиям, проведение конференций)

Индивидуальные проекты Индивидуальные проекты Осуществляются национальными или международными группами ученых по новым актуальным научным направле-ниям во взаимодействии с Европейским научно-исследовательским советом Поддержка совершенствования и карьерного роста ученых Осуществляется через систему грантов им. Марии Кюри

Сети 7РП В рамках схемы Coordination and Support Action Еврокомиссия создала ряд сетей: IncoNet EECA http://www.inco-eeca.net IncoNet CA/SC - S&T International Cooperation Network for Central Asian and South Caucasus Countries http://icbss.org/index.php?option=com_content&task=view&id=273 incrEAST - Information Exchange in Science and Technology between the European Research Area and Eastern European / Central Asian Countries http://www.increast.eu/ HEALTH-NCP-NET http://www.healthncpnet.eu/jahia/Jahia/ INCONTACT network of the INCO-NCPs http://www.ncp-incontact.eu/nkswiki/index.php?title=Main_Page HITT-CIS - Health In Times Transition: Trends in Population Health and Health Policies in CIS countries http://www.hitt-cis.net/

ERA-NETs: ERA-NETs: ERA.NET RUS Linking Russia to the ERA: Coordination of MS´/AC´ S&T programmes towards and with Russia http://www.era.net-rus.eu/, http://ec.europa.eu/research/iscp/pdf/russia_eranet.pdf BS-ERA.NET Networking on science and technology in the Black Sea region http://www.bs-era.net/main/index.php?we=9bfdbe988abcff430168e60524a69c11&wchk=c1960ad06e70dbaee80ab8641db51532, http://ec.europa.eu/research/iscp/pdf/black_sea.pdf BILATs BILAT-RUS Enhancing the bilateral S&T Partnership with the Russian Federation http://www.bilat-rus.eu/, http://ec.europa.eu/research/iscp/pdf/russia_bilat.pdf BILAT-UKR Enhancing the bilateral S&T Partnership with Ukraine, http://www.bilat-ukr.eu/, http://ec.europa.eu/research/iscp/pdf/ukraine.pdf

Participation and Success Rate in FP7 Health Research The countries of Eastern Europe and Central Asia include: Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, the Russian Federation, Turkmenistan, Tajikistan, Ukraine and Uzbekistan. (EECAlink focuses on those underlined) FP6: Armenia (3 - 250k€), Belarus (1 - 22k€), Ukraine (8 - 650k€), Russia (38 - €5.8Mio) FP7: Armenia (8/2/25%), Belarus (12/2/17%) , Georgia (10/4/40%), Kazakhstan (9/2/22%), Moldova (7/3/43%), Russia (113/25/22%), Ukraine (28/5/18%), Uzbekistan (2/1/50%) CPM Status March 2010

5-ый конкурс «Здоровье» Бюджет: €650m Дата объявления: 30 July 2010 Последняя дата внесения проектов : FP7-HEALTH-2011-single-stage, deadline: 10 Nov. 2010 (tbc) FP7-HEALTH-2011-two-stage, deadline: 13 Oct. 2010 (tbc)

Некоторые данные по 7РП «Здоровье» FP7 HEALTH Proposals received все страны- 21’829 , третьи страны 1464 N° of participations 2315 591 Grant Agreements 405 123 (N° of participations 4241 327 EU funding €1’606 Mio

Приоритеты 5-ого конкурса Области главных приоритетов: the brain: neurodegenerative + lifestyle-related aspects diabetes/obesity & lifestyle-induced conditions antimicrobial drug resistance emerging epidemics health inequalities, … Исследовательские инициативы высокой значимости: Epigenomics Better immunisation

Исследовательские инициативы высокой значимости Major strategic investments to foster European competitive position in target areas with important economical/societal return Programmatic approach (structuring the ERA): several research components integrated in each project, allowing synergies. High-impact outcomes expected from coherent & ambitious strategies Collaborative Project, but larger in size (€30 Mio) Participation of SMEs (min. 15% of EU contribution to each project) Governance and management will be critical. Adapted evaluation: single-stage, with hearings

Тематика клинических испытаний Руководящие принципы: Двустадийная схема внесения Вклад EC : max. €6m/project in most cases Читсло партнеров: в каждом случае свое (with minimum 3) Продолжительность проектов: по усмотрению заявителей Поощряется участие больных Предусмотрены этические моменты (EU and national) Возможно участие субподрядчиков

Тематика клинических испытаний Цель: Translating research into clinical practice Focus on investigator-driven CTs – relevant to public health

SME участие Одна из задач: облегчить и увеличить участие SME

Принципы междуна- родного сотрудничества Болезни не имеют границ, поража-ют население богатых и бедных стран Здоровье является политическим приоритетом для большинства стран (богатых и бедных) Болезни богатых (рак, диабет, сер-дечно-сосудистые заболевания и др. ) поражают население развиваю-щихся стран и, наоборот (малярия, туберкулез,…). Лечение всегда универсально

Все темы открыты для участников из третьих стран Все темы открыты для участников из третьих стран Некоторые темы имеют целевое значение Ряд тем получил название Specific International Cooperation Actions (так называемые SICAs) Address specific issues that partner countries face or have a global character, on the basis of mutual interest and benefit

Ключевые факторы успеха Предложения должны быть адресованы тематике, рабочей программе, конкретными не расплывчатыми; (not wishful thinking) Консорциум партнеров должен быть превосходным и соответствовать задачам (select the right partners) Предложения должны соответствовать всем требуемым критериям Должны быть убедительными для рецензента (don’t rely on reputation) Соответстовать основным правилам (deadlines, N° of participants, ceilings, length, ethics

3 критерия соответствия; 3 критерия соответствия; Пороги Science & Technology excellence 3/5 Implementation & Management 3/5 Potential Impact 3/5 Overall 10/15

Европейское исследовательское пространство (R&D aria) 27 EU Member States +7 Outermost Regions Guadeloupe, French Guiana, Martinique and Réunion (the four French overseas departments), the Canaries (Spain), and the Azores and Madeira (Portugal) +12 Associated Countries (the EU neighbourhood countries) Albania, Bosnia and Herzegovina, Croatia, Iceland , Israel, Liechtenstein, FYR of Macedonia, Norway, Republic of Montenegro, Serbia, Switzerland, Turkey +FP7 Third Countries Other countries worldwide - can participate in FP7 - some can receive funding (ICPC, incl. BRICS) and others only exceptionally (high-income countries)

Участие третьих стран

Участие Восточноевропейских стран (2007-2010) Участие Восточноевропейских стран (2007-2010) Russia: 35 Ukraine: 6 Georgia: 5 Rep.Moldova: 4 Belarus: 3 Armenia, Kazakhstan: 2 Uzbekistan: 1

Требования и финансирование Для большинства типов проектов (CP-IPs, small/medium CP-FPs): Минимальное число участников: 3 из MS/AS Средний объем: большой CP-IPs – €10.7 Mio /17 partners, средний CP-FP - €3.5 Mio / 10 partners, малый CP-TP – €3.2 Mio / 8 partners Средний показатель участия третьих стран: 30% по грантам, 8% по участникам Specific International Cooperation Actions Минимальное число участников: 2+2 (2 from MS/AS + 2 from ICPCs) В среднем от третьих стран: 4 partners Средний объем: CP-SICA - €3.4 Mio / 9 partners (5 MS/AS + 4 TC)

Возможности 5-ого конкурса c точки зрения сотрудничества Programme-Level Cooperation with: Russia: 1.1-3 HTP Proteomics Brazil: 1.1.4-5 Inflammatory and Autoimmune diseases India: 2.2.1-4 Neurodegenerative paediatric diseases India: 2.4.1-3 Cancer from Infectious Agents Brazil: 3.4-3 Multilateral cooperation in Public Health Specific International Cooperation Actions: 2.1.1-4 Pop. Genetics on Cardio-Metabolic Disorders 2.3.3-2 Control of Dengue Fever 2.4.3-4 Obesity and/or Diabetes in Specific Populations 3.4-1 Reproductive Health and Health Equity Other topics of particular international nature: 2.3.3-1 Zoonotic Viruses 2.3.3-3 Major Epidemic Outbreaks 2.3.1-2 Evolution/transfer of AMDR 3.3-1 Determinants of Health 3.4-2 Research Capacity

Где искать информацию? Calls for Proposals, Work Programme (Topics) http://cordis.europa.eu/fp7/health/ National Contact Points (NCPs) - Information & support for applicants http://www.healthncpnet.eu FP6/FP7 projects databases http://www.lifecompetence.eu/; http://www.healthcompetence.eu/ Partner search tools http://www.smesgohealth.org/ EU health research website http://ec.europa.eu/research/health/

Proposed topics for 2011 WP Activity 1 - Биотехнология, мето- ды и технологии для медицины

Биотехнология, мето- ды и технологии 1.1 – High-throughput research 1.1-1 SME-targeted research for developing tools and technologies for high-throughput research. Funding scheme: collab. project, max €6m, 2-stage, one or more proposals. 1.1-2 Genome-based biomarkers for patient stratification and pharmacogenomic strategies. Funding scheme: collab. project, max €6m, 2-stage, one or more proposals. 1.1-3 High-throughput proteomics for human health and disease. (Russia) Funding scheme: collab. project, max €3m, single-stage, one or more proposals.

Биотехнология, мето- ды и технологии 1.2 - Detection, diagnosis and monitoring Closed in 2011 1.3 - Suitability, safety, efficacy of therapies Closed in 2011

Биотехнология, мето- ды и технологии 1.4 Innovative therapeutic approaches and interventions 1.4-1 Regenerative medicine clinical trials. Funding scheme: collab. project, max €6m, 2-stage, one or more proposals. 1.4-2 Tools, technologies and devices for application in regenerative medicine. Funding scheme: collab. project, max €6m, 2-stage, one or more proposals. 1.4-3 Development and production of new, high-affinity protein scaffolds for therapeutic use. Funding scheme: collab. project, max €6m, 2-stage, one or more proposals.

Биотехнология, мето- ды и технологии 1.4 – Innovative therapeutic approaches and interventions 1.4-4 High impact project immunisation. Funding scheme: collab. project, max €30m, single-stage, max one proposal. 1.4-5 New therapeutic approaches in chronic inflammatory and autoimmune diseases. (Brazil) Funding scheme: collab. project, max €3m, single-stage, one or more proposals

Proposed topics for 2011 WP Proposed topics for 2011 WP Activity 2 - Сквозные исследова- ния в области здоровья (translating research for human health)

Сквозные исследова- ния в области здоровья 2.1.1 – large-scale data-gathering: 2.1.1-1 High impact initiative on the human epigenome. Funding scheme: collab. project, max €30m, single-stage, max one proposal. 2.1.1-2 Proteins and their interactions in health and disease. Funding scheme: collab. project, max €12m, 2-stage, one or more proposals. 2.1.1-3 Large-scale genomics approaches to identify host determinants of infectious diseases. Funding scheme: collab. project, max €12m, single-stage, max one proposal. 2.1.1-4 Population genetic studies on cardio-metabolic disorders in EU/AC and EECA populations. Funding scheme: Specific International Cooperation Action (SICA), collab. project, max €6m, single-stage, max one proposal.

Сквозные исследова- ния в области здоровья 2.1 – Integrating biological data and processes 2.1.2 – Systems biology Closed in 2011.

Сквозные исследова- ния в области здоровья 2.2.1 – Research on the Brain and related diseases, human development and ageing: 2.2.1-1 Investigator-driven clinical trials for childhood-onset neurodegenerative diseases. Funding scheme: collab. project, max €6m, 2-stage, one or more proposals. 2.2.1-2 Understanding the role of neuroinflammation in neurodegenerative diseases. Funding scheme: collab. project, max €12m, 2-stage, one or more proposals. 2.2.1-3 Addictive and/or compulsive behaviour in children & adolescents: translating preclinical results into therapies Funding scheme: collab. project, max €6m, 2-stage, one or more proposals.

Сквозные исследова- ния в области здоровья 2.2.1 – Research on the Brain and related diseases, human development and ageing: 2.2.1-4 Creating clinical and molecular tools for experi-mental therapy of paediatric neurodegenerative disorders causing childhood dementia in Europe and India. Funding scheme: collab. project, max €3m, single-stage, one or more proposals. 2.2.1-5: ERA-Net on disease-related neuroscien-ces. Funding scheme: CA ERA-NET, ~€2m, single-stage, max. one proposal.

Сквозные исследова- ния в области здоровья 2.2.2 – Human development and ageing: 2.2.2-1 Investigator-driven clinical trials for therapeutic interventions in elderly populations. Funding scheme: collab. project, max €6m, 2-stage, one or more proposals. 2.2.2-2 Linking human development and ageing. Funding scheme: collab. project, max €3m, 2-stage, one or more proposals.

Сквозные исследова- ния в области здоровья 2.3-1 Anti-microbial drug resistance 2.3.1-1 Investigator-driven clinical trials of off-patent antibiotics. Funding scheme: collab. project, max €6m, 2-stage, one or more proposals. 2.3.1-2 Multi-disciplinary research on the evolution and transfer of antibiotic resistance. Funding scheme: collab. project, max €12m, single-stage, max one proposal. 2.3.1-3 Management of Gram negative multi-drug resistant infections. Funding scheme: collab. project, max €12m, single-stage, max one proposal.

Сквозные исследова- ния в области здоровья 2.3-1 Anti-microbial drug resistance 2.3.1-4 Development of multi-analyte diagnostic tests. Funding scheme: collab. project, max €3m, 2-stage, one or more proposals. 2.3.1-5 Development of tools to control microbial biofilms with relevance to clinical drug resistance. Funding scheme: collab. project, max €3m, 2-stage, one or more proposals.

Сквозные исследова- ния в области здоровья 2.3.2 – HIV/AIDS, malaria and tuberculosis Closed in 2011

Сквозные исследова- ния в области здоровья 2.3.3 – Potentially new and re-emerging epidemics 2.3.3-1 Identification of factors promoting the emergence of pathogens with human pandemic potential from pathogens with a zoonotic background and related prevention strategies. Funding scheme: collab. project, max €12m, two-stage, max one proposal. 2.3.3-2 Comprehensive control of Dengue fever under changing climatic conditions. (SICA: Latin Am. & Asia) Funding scheme: collab. project, max €6m, single-stage, one or more proposals. 2.3.3-3 Development of an evidence-based behavioural and communication package to respond to major epidemic outbreaks. Funding scheme: collab. project, max €2m, 2-stage, one or more proposals.

Сквозные исследова- ния в области здоровья 2.3.4 – Neglected infectious diseases Closed in 2011

Сквозные исследова- ния в области здоровья 2.4.1 – Cancer 2.4.1-1 Investigator-driven, treatment trials for rare cancers. Funding scheme: collab. project, max €6m, 2-stage, one or more proposals. 2.4.1-2 Translational research on cancers with poor prognosis Funding scheme: collab. project, max €3m, 2-stage, one or more proposals. 2.4.1-3 Epidemiology and aetiology of infection-related cancers (in Europe & India) Funding scheme: collab. project, max €3m, 1-stage, one or more proposals.

Сквозные исследова- ния в области здоровья 2.4.2 – Cardiovascular disease 2.4.2-1 Investigator-driven clinical trials for the management of cardiovascular diseases. Funding scheme: collab. project, max €12m, 2-stage, one or more proposals. 2.4.2-2 Evaluation and validation studies of clinically useful biomarkers in prevention and management of cardiovascular disease. Funding scheme: collab. project, max €6m, 2-stage, one or more proposals.

Сквозные исследова- ния в области здоровья 2.4.3 – Diabetes and obesity 2.4.3-1 Investigator-driven clinical trials to reduce diabetes complications. Funding scheme: collab. project, max €6m, 2-stage, one or more proposals. 2.4.3-2 Development of novel treatment strategies based on knowledge of cellular dysfunction. Funding scheme: collab. project, max €6m, 2-stage, one or more proposals. 2.4.3-3 Molecular and physiological effects of lifestyle factors on diabetes/obesity. Funding scheme: collab. project, max €6m, 2-stage, one or more proposals.

Сквозные исследова- ния в области здоровья 2.4.3 – Diabetes and obesity 2.4.3-4 Genetic and environmental factors in obesity and/or diabetes in specific populations. Funding scheme: SICA (Africa, Asia, Latin America, Mediterranean countries), max €3m, 2-stage, one or more proposals. 2.4.3-5 ERA-NET on diabetes prevention and treatment. Funding scheme: ERA-NET CA, ~€2m, single-stage, max one project.

Сквозные исследова- ния в области здоровья 2.4.4 – Rare diseases Closed in 2011 2.4.5 – Other chronic diseases Closed in 2011

Proposed topics for 2011 WP Proposed topics for 2011 WP Activity 3 - Оптимизация ока- зания лечебной помощи- (Optimising the delivery of health care)

Оптимизация ока- зания лечебной помощи 3.1 – Translating the results of clinical research outcome into clinical practice Closed in 2011 3.2 – Quality, efficiency and solidarity of healthcare systems Closed in 2011.

Оптимизация ока- зания лечебной помощи 3.3 – Health promotion 3.3-1 Developing methodologies to reduce inequities in the determinants of health. Funding scheme: collab. project, max €3m, 2-stage, one or more proposals. 3.3-2. Analysis of integrated strategies for sustainable behaviour change. Funding scheme: collab. project, max €3m, 2-stage, one or more proposals. 3.3-3 Developing and implementing methods for the transfer of research into policy in the fields of health promotion and disease prevention. Funding scheme: collab. project, max €3m, single-stage, max one proposal. 3.3-4 A road-map for mental health research in Europe. Funding scheme: CA, max €2m, single-stage, max one proposal.

Оптимизация ока- зания лечебной помощи 3.4 – International public health & health systems 3.4-1 Development and assessment of comprehensive and integrated interventions and programmes to improve repro-ductive health and health equity. Funding scheme: SICA (all ICPC) collab. project, max €3m, single-stage, one or more proposals. 3.4-2 Building sustainable capacity for research for health and its social determinants in low and middle income countries. Funding scheme: CA, max €2m, single-stage, one or more proposals. 3.4-3 Multilateral cooperation between Europe, Africa and Latin America on public health and health services research. Funding scheme: CA, max €2m, single-stage, max one proposal.

Proposed topics for 2011 WP Proposed topics for 2011 WP Activity 4 - Мероприятия поддержки и ответ на требования политики (support actions & response to policy need)

Мероприятия поддержки 4.1 – Coordination and support actions across the theme 4.1-1 Networking of major research institutions to coordinate communication actions aimed at the media and the general public. Funding scheme: CA, max €2m, single-stage, max one proposal. 4.1-2 Targeting publication bias. Funding scheme: SA, max €0.5m, single-stage, one or more proposals. 4.1-3 Linking EU and Latin American policy-making institutions in the field of health research. Funding scheme: CA, max €2m, single-stage, max one proposal. 4.1-4 Organisation of supporting actions and events related to the presidency of the EU. Funding scheme: SA, max €100,000, single-stage, one or more proposals.

Мероприятия поддержки 4.2 – Responding to EU Policy needs 4.2-1 Investigator-driven clinical trials on off‑patent medicines for children. Funding scheme: collab. project, max €6m, single-stage, one or more proposals. 4.2-2 Adverse drug reaction research. Funding scheme: collab. project, max €3m, single-stage, one or more proposals. 4.2­3 New methodologies for clinical trials in personalised medicine. Funding scheme: collab. project, max €3m, single-stage, one or more proposals.

ГНУ «Институт биофизики и клеточной инженерии НАН Беларуси» ГНУ «Институт биофизики и клеточной инженерии НАН Беларуси» Tel.: (+375 17) 284-17-49 Fax: (+375 17) 284-23-59 E-mail: ibce@basnet.by WWW: http://www.ipb.org.by/ - войти в раздел « общая информация», а затем – «НКТ»